மருந்து கஞ்சா அறிக்கை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
ResearchAndMarkets.com s offering.
The rapid growth of cannabis-based medicines is becoming a significant disruptor of the global pharmaceutical industry, but the point of entry has been complicated by the historic scheduling of cannabis as a schedule 1 narcotic. However, pharmaceutical cannabis products such as Epidyolex, Sativex and Dronabinol have become serious alternatives to traditional pharmaceuticals and are beginning to shift how the pharma industry approaches cannabis.
Clinical trials and academic studies are on the rise, constantly changing our understanding of the cannabis plant. In tandem, commercial opportunities are emerging as innovation, capital and technology create a space for a new form of cannabis-based medicines, which will change the way we medicate over the next 5-10 years. This report unpacks the regulatory landscape across key markets, analyses the key trends which are changing the face of the market ....

Octarine Bio , Laura Wood , E St Office Hours Call , Arena Pharmaceuticals , Office Hours Call , Zynerba Pharmaceuticals , Corbus Pharmaceuticals , Precigen Inc , Impact Series , Pharmaceutical Cannabis , Pharmaceutical Cannabis Report , Topics Covered , Drug Profiles , Brand Activity , Senior Manager , Free Call , Hours Call , Research And Markets , லாரா மரம் , ஏ ஸ்டம்ப் அலுவலகம் மணி அழைப்பு , அரங்கம் மருந்துகள் , அலுவலகம் மணி அழைப்பு , கார்பஸ் மருந்துகள் , தாக்கம் தொடர் , மருந்து கஞ்சா , மருந்து கஞ்சா அறிக்கை ,